Jupiter Neurosciences (JUNS) said Monday that it signed an agreement with Catalent Pharma Solutions for the production of Jotrol softgel capsules for Jupiter's upcoming phase 2a clinical trial in Parkinson's disease.
Jotrol is Jupiter's oral formulation of resveratrol and under the deal, Catalent will manufacture clinical batches of Jotrol using a softgel formulation, according to the statement. No financial details were disclosed.
Jupiter said the production will include active and placebo batches for its planned Parkinson's study, which will evaluate Jotrol's safety, tolerability, and pharmacokinetics in patients with Parkinson's disease over a three-month period.
Shares of Jupiter Neurosciences were down more than 9% in recent Monday trading.
Price: 0.93, Change: -0.10, Percent Change: -9.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.